OncoMatch/Clinical Trials/NCT07737951
Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia
Is NCT07737951 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for hormone receptor positive breast carcinoma.
The objective of the pilot RCT is to evaluate the feasibility and acceptability of a Tai Chi intervention "TaiChi4Joint" vs. an HE AC group for relieving AIIA in women with hormone receptor positive stage I-III BCa. The investigators will pilot test our data collection for mechanism measures via three innovatively integrated biobehavioral pathways.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 expression
hormone receptor-positive breast cancer
Disease stage
Required: Stage I, II, III
Demographics
Prior therapy
Must have received: aromatase inhibitor (anastrozole, letrozole, exemestane)
Currently receiving an aromatase inhibitor (anastrozole, letrozole, or exemestane) or within 5 years of initiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sidney Kimmel Cancer Center at Thomas Jefferson University · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07737951 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received aromatase inhibitor.
Does this trial require ESR1?
Yes, ESR1 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages